Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and (b) an additional therapeutic agent. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and an additional therapeutic agent.

Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an additional agent. The additional agent can be a compound selected from a PPAR-? agonist, a PPAR-? agonist, and a dual PPAR-? and PPAR-? agonist, or a pharmaceutically acceptable salt thereof; or a TR? agonist, or a pharmaceutically acceptable salt thereof; or an omega 3 fatty acid, or a pharmaceutically acceptable salt or ester thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an additional agent.

Abstract: Provided herein are methods and combination therapies useful for the treatment of cancer. In particular, provided herein are methods and combination therapies for treating cancer by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one DNA damaging agent, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an antioxidant, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and an antioxidant, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an additional therapeutic agent, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and (b) an SGLT-2 inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and/or (c) a GLP-1 receptor agonist, or a pharmaceutically acceptable salt or solvate thereof, and/or (d) metformin. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising the compound of Formula (I) and an SGLT-2 inhibitor and/or a GLP-1 receptor agonist and/or metformin.

Abstract: Provided herein are methods for treating or preventing pulmonary fibrosis in subjects suffering from diffuse parenchymal lung diseases using selective active-site mTOR inhibitors.

Abstract: Embodiments are related to new uses for selective active-site mTOR inhibitors in treating or preventing pulmonary fibrosis in diffuse parenchymal lung disease (DPLD) patients, such as a DPLD of environmental cause, a collagen vascular disease (e.g., scleroderma and rheumatoid arthritis), an idiopathic interstitial pneumonia (e.g., idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia), and sarcoidosis.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.

Abstract: A synergistic combination of ligands that interact with death domain receptors, and diterpenoid triepoxides is used to increase tumor cell killing by induction of apoptosis. Ligands useful in the invention include TRAIL, TNF-&agr;, analogs thereof, stabilized multimers thereof, mimetics, etc. Of particular interest are combined therapy with the diterpenoid triepoxides triptolide and derivatives and analogs thereof.

Abstract: Combinations of diterpenoid triepoxides and anti-proliferative agents are used in a combination therapy to treat hyperproliferative disorders. Anti-proliferative agents of interest include agents active in killing tumor cells, as well as immunosuppressants, and a variety of other agents that reduce cellular proliferation in targeted tissues. Synergistic combinations provide for comparable or improved therapeutic effects, while lowering adverse side effects.